New lung cancer cocktail aims to outperform current standard
NCT ID NCT07170995
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests whether a new combination of drugs (SHR-8068, adebrelimab, and chemotherapy) works better than the current standard treatment (tislelizumab plus chemotherapy) for people with advanced or metastatic non-small cell lung cancer who have not had prior treatment. About 460 adults aged 18-75 will participate. The goal is to see if the new combo delays cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, 250117, China
Contact
Conditions
Explore the condition pages connected to this study.